Cytokine secretion from activated hepatic stellate cells

The term "cytokine secretion from activated hepatic stellate cells" does not refer to a single, specific molecular target or receptor, but rather describes a biological process involving the release of multiple cytokines and chemokines (such as CCL2, IL-6, IL-10, TNF-α, TGF-β, and others) by activated hepatic stellate cells (HSCs) in the liver[1][5][2][3]. This secretion occurs in response to liver injury, inflammation, or fibrosis and contributes to immune cell recruitment, activation, and disease progression, including liver fibrosis and hepatocellular carcinoma. While individual cytokines or receptors (e.g., CCL2/CCR2, TGF-β, PDGF) are bona fide drug targets, the process itself is not a discrete therapeutic target, so the entry as written is too broad and not in line with conventional molecular target naming. Summary of issues: - The entry is conceptually referential ("cytokine secretion") rather than discrete (no single molecule or receptor). - A proper target would be a specific cytokine (e.g., "CCL2"), a receptor (e.g., "CCR2" or "PDGF receptor beta"), or "Activated hepatic stellate cell" if discussing cell-based therapies. - If using this information for structured databases, consider splitting into individual cytokines or surface receptors for pharmacological targeting.